Latest Androgel Stories
NORTH CHICAGO, Ill., Jan. 30, 2013 /PRNewswire/ -- AbbVie today confirmed it delivered strong sales growth with its marketed pharmaceutical products in 2012. The proprietary pharmaceutical segment of Abbott, representing the majority of AbbVie's revenue, grew more than 8 percent globally on an operational basis, excluding a nearly 3 percent negative impact from foreign exchange. Performance was driven by solid double-digit growth from both HUMIRA and AndroGel and...
MedicationDiscountCard.com is pleased to announce that their prescription discount card now functions as an Androgel coupon. (PRWEB) January 23, 2013 MedicationDiscountCard.com is pleased to announce that their prescription discount card now functions as an Androgel coupon. Androgel is a topical hormonal treatment for men. Because of its high price, it is sometimes out of reach even for patients who demonstrate a medical need. That's when an Androgel coupon can save the day. Low...
Blau, Brown & Leonard, LLC, are investigating the possible link of the drug Androgel to various blood clot disorders in men, including Pulmonary Embolisms and Deep Vein Thrombosis. The law firm has a 24/7 phone number at (800) 9100-LAW for anyone who has experienced such a side effect from Androgel. New York, NY (PRWEB) September 02, 2012 Blau, Brown & Leonard, LLC a law firm that litigates pharmaceutical cases nationwide is investigating the link between Androgel and certain...
ABBOTT PARK, Ill., April 29, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved AndroGel® (testosterone gel) 1.62%, a clear, odorless, gel formulation shown to restore testosterone levels in hypogonadal men with half the volume of gel at the starting dose compared to AndroGel 1%. At the starting dose, the new AndroGel 1.62% contains 40.5 mg of testosterone in two pump presses, whereas AndroGel 1% contains 50 mg of...
Commercials targeting U.S. middle-age men with lowered sex drive and melancholy moods may be scientifically unfounded, experts say. The Milwaukee Journal Sentinel reported Saturday the advertisements and the study from which their data is gleaned was funded by Solvay Pharmaceuticals, and the company allegedly entered into conspiracy with generic drug manufacturers to keep generic testosterone medications off the market. Over the last several years, the demand for Solvay's Androgel has...
Food and Drug Administration officials are warning parents to keep prescription testosterone gel far from children due to its serious side effects. Testosterone can be good in some instances for adults, but the hormone can cause problems in children such as enlargement of the genital organs, aggressive behavior, early aging of the bones, premature growth of pubic hair, and increased sexual drive.The agency says both boys and girls are at risk, and has ordered its strongest warning on the...
LANCASTER, Pa., April 7 /PRNewswire-USNewswire/ -- A class action complaint filed last week in New Jersey federal court claims damages for violations of the Sherman Antitrust Act by brand-name and generic manufacturers of the drug, Androgel. The case, filed by Stephen L. LaFrance Pharmacy, Inc. d/b/a SAJ Distributors and Stephen L. LaFrance Holdings, Inc., names as Defendants Unimed Pharmaceuticals Inc., Solvay Pharmaceuticals Inc., Watson Pharmaceuticals Inc., Par Pharmaceuticals, Inc....
WOODCLIFF LAKE, N.J., Feb. 2 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it learned after the close of business on Friday, January 30, 2009 that the Federal Trade Commission and the California Attorney General filed a lawsuit against Par in the U.S. District Court for the District of Central California. The FTC lawsuit makes antitrust and other allegations about a patent settlement agreement that was approved by the U.S. District Court for...
CORONA, Calif., Feb. 2 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that the U.S. Federal Trade Commission (FTC) and the State of California have filed a lawsuit in the United States District Court for the Central District of California alleging that the Company's 2006 patent lawsuit settlement with Solvay Pharmaceuticals Inc. related to AndroGel(R) 1% (testosterone gel)...
MARIETTA, Ga., June 17 /PRNewswire/ -- Solvay Pharmaceuticals, Inc. announced today that a new analysis of pivotal study data conducted by the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center showed that initial treatment response of hypogonadal men with AndroGel(R) (testosterone gel) 1% CIII had similar effects on subjects, regardless of weight and body mass index (BMI). These study results were presented today at the 2008 Endocrine Society Annual Meeting (ENDO) in...
